Key Points
- Insider sale: Bruker VP Mark Munch sold 2,000 shares on April 15 at $39.90 for $79,800, trimming his stake to 128,443 shares (a 1.53% decrease); he also sold 2,000 shares on March 13 at $35.44.
- Bruker missed Q results on EPS ($0.59 vs. $0.65 forecast) but posted $977.2M in revenue, and set FY2026 guidance of $2.10–$2.15 EPS while analysts maintain a consensus "Hold" with an average target of $49.38.
- Shares opened at $38.94 (down ~1.4%), trading in a 52-week range of $28.53–$56.22; the company pays a $0.05 quarterly dividend (0.5% yield) and institutional investors own about 79.5% of the stock.
Bruker Corporation (NASDAQ:BRKR - Get Free Report) VP Mark Munch sold 2,000 shares of Bruker stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total transaction of $79,800.00. Following the transaction, the vice president directly owned 128,443 shares of the company's stock, valued at $5,124,875.70. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Mark Munch also recently made the following trade(s):
- On Friday, March 13th, Mark Munch sold 2,000 shares of Bruker stock. The stock was sold at an average price of $35.44, for a total transaction of $70,880.00.
Bruker Stock Down 1.4%
Shares of BRKR opened at $38.94 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $56.22. The firm has a market capitalization of $5.93 billion, a price-to-earnings ratio of -259.60, a PEG ratio of 2.36 and a beta of 1.20. The business's fifty day moving average price is $37.47 and its two-hundred day moving average price is $41.68.
Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts' consensus estimates of $0.65 by ($0.06). The business had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.Bruker's revenue was down .2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.
Bruker Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Monday, March 23rd. Bruker's dividend payout ratio (DPR) is presently -133.33%.
Analysts Set New Price Targets
Several analysts recently issued reports on the company. Jefferies Financial Group set a $50.00 target price on Bruker in a report on Thursday, February 12th. Citigroup decreased their price target on shares of Bruker from $53.00 to $40.00 and set a "neutral" rating on the stock in a research note on Friday, February 13th. TD Cowen upgraded Bruker to a "hold" rating in a research report on Monday. The Goldman Sachs Group dropped their price target on shares of Bruker from $40.00 to $35.00 and set a "sell" rating for the company in a research report on Friday, February 13th. Finally, Barclays decreased their target price on shares of Bruker from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $49.38.
Check Out Our Latest Stock Report on BRKR
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP raised its holdings in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company's stock worth $29,000 after buying an additional 257 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Bruker by 6.7% during the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company's stock valued at $284,000 after purchasing an additional 380 shares during the last quarter. Linden Thomas Advisory Services LLC increased its position in shares of Bruker by 2.1% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 19,669 shares of the medical research company's stock valued at $639,000 after purchasing an additional 396 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Bruker by 1.4% during the 3rd quarter. Arizona State Retirement System now owns 31,369 shares of the medical research company's stock worth $1,019,000 after purchasing an additional 435 shares during the period. Finally, Parallel Advisors LLC boosted its holdings in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company's stock worth $41,000 after buying an additional 479 shares during the last quarter. Institutional investors own 79.52% of the company's stock.
About Bruker
(
Get Free Report)
Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.
Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.
In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
